CHALLENGES
Solid-State Challenges in Pharmaceutical Development
A material may meet its chemical specification and still present unanswered questions about solid form, structure, physical stability or crystallization behavior. These uncertainties can affect decisions in API development, technology transfer and dosage-form development. TeraCrystal approaches each challenge by defining the scientific question, selecting a proportionate investigation and interpreting the results in the context of the next development decision.
Polymorphism and Solid-Form Selection
The same molecule may occur in different crystalline arrangements or related solid forms, including solvates, hydrates, salts and co-crystals. These forms may differ in physical properties and behavior under development conditions. The challenge is not simply to detect multiple forms, but to understand their identity, relationships and relevance to the intended product. We help teams frame form-selection questions, investigate candidate forms and evaluate evidence that supports a reasoned development choice.
Unknown Structures and Difficult Phase Identification
Unexpected diffraction patterns, very small crystals or ambiguous phase assignments can leave a development team uncertain about what material it actually has. In some cases, the distinction between a salt and a co-crystal, or between related crystalline phases, matters for scientific interpretation and further development. Structural investigations can help resolve these questions when appropriate material and analytical approaches are available.
Phase Transformations and Crystallization Risks
Solid forms can change as conditions change. Solvent exposure, temperature, water content, isolation, drying or storage may alter phase composition or crystal characteristics. A crystallization route that produces the desired material in one setting may require further understanding before it can be applied consistently in another. We investigate transformation behavior and crystallization-related variables to support process-development choices and risk discussions.
Solubility, Stability and Development Performance
The relevance of a solid form extends beyond its crystal structure. Solubility, dissolution behavior, physical stability and particle attributes may influence downstream processing or formulation development. For oral solid dosage forms, the API-to-formulation interface can be important; in selected semisolid systems, crystallization or recrystallization during processing or storage may also warrant investigation. We help teams identify which material questions require targeted scientific work before conclusions are drawn.
Turning Scientific Findings into a CMC Development Plan
Promising scientific results need to be translated into a practical plan for development, regulatory documentation and reliable supply. Teams may need to identify CMC gaps, prioritize studies, select a CDMO or prepare a technology transfer. Our advisory collaboration connects these decisions with the programme's development stage and available evidence.
Start with the Decision, Not the Technique
A useful investigation begins with a defined question: What is the uncertain material attribute? What decision depends on it? Which evidence is already available? What would constitute a meaningful result? By clarifying the decision first, scientific work can be focused on information that is relevant to development.